2023-08-08 11:14:51 ET
- Specialty cancer diagnostics company Precipio ( NASDAQ: PRPO ) on Tuesday announced the launch of its new quantitative BCR-ABL 2.0 panel.
- Precipio's HemeScreen BCR-ABL 2.0 assay stands out as the sole market panel offering quantitative coverage for four crucial breakpoints, unlike other products that offer only single breakpoint, according to the company.
- The BCR-ABL 2.0 panel includes an automated analysis software, delivering direct analysis result into the laboratory’s systems, eliminating manual steps and saving time and labor cost, Precipio added.
- Source: Press Release
For further details see:
Precipio launches quantitative BCR-ABL 2.0 panel for patients with chronic myeloid leukemia